This review delves into the rapidly evolving landscape of liquid biopsy technologies based
on cell-free DNA (cfDNA) and cell-free RNA (cfRNA) and their increasingly prominent role in …

Cell-free fetal DNA (cffDNA) is released into the maternal circulation from trophoblastic cells
during pregnancy, is detectable from 4 weeks and is representative of the entire fetal …

Key points What is already known about this topic? In 2015, the International Society for
Prenatal Diagnosis (ISPD) published its first position statement on the use of non‐invasive …

Due to the favorable test characteristics of the non-invasive prenatal test (NIPT) in the
screening of fetal aneuploidy, there has been a strong and growing demand for …

Prenatal screening for sex chromosome aneuploidies (SCAs) is increasingly available
through expanded non‐invasive prenatal testing (NIPT). NIPT for SCAs raises complex …

Pregnant women's perspectives should be included in the dialogue surrounding the
expanding offers of non-invasive prenatal testing (NIPT), especially now that technological …

Abstract Background The Netherlands and Belgium have been among the first countries to
offer non‐invasive prenatal testing (NIPT) as a first‐tier screening test. Despite similarities …

Non-invasive prenatal testing (NIPT) has been available commercially in Europe since
approximately 2012. Currently, many countries are in the process of integrating NIPT into …

In recent years, as the implementation and use of Non‐Invasive Prenatal Testing (NIPT)
have increased, the cost of the test has been decreasing. The cost of NIPT is expected to fall …

Background The introduction and wide application of non-invasive prenatal testing (NIPT)
has triggered further evolution of routines in the practice of prenatal diagnosis.'Routinization' …